May 2 (Bloomberg) -- Zealand Pharma A/S, the Danish drugmaker, rose the most in seven weeks in Copenhagen trading after partner Sanofi said it will step up commitment to develop diabetes treatment Lyxumia as a rival drug faces setbacks.
The Glostrup, Denmark-based drugmaker advanced 2.6 percent, the most since March 13, to 79 kroner with trading volume at 78 percent of the three-month daily average.
Lyxumia is used in combination with Paris-based Sanofi’s Lantus drug to help stimulate the production of insulin and is set to compete with Novo Nordisk A/S’s experimental medicine Tresiba. Bagsvaerd, Denmark-based Novo said yesterday it may take five more years to gain U.S. approval to sell the drug after regulators requested additional tests.
Tresiba’s delay is “really good news for us,” Sanofi Chief Executive Officer Chris Viehbacher said today on a conference call. “Priority has been assigned to a fixed-ratio combination of Lantus/Lyxumia” after the “recent competitor setback in the U.S.,” the drugmaker said in its earnings report.
To contact the reporter on this story: Christian Wienberg in Copenhagen at firstname.lastname@example.org
To contact the editor responsible for this story: Tasneem Brogger at email@example.com